Artelo Biosciences Inc
ARTL
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.53M
Close$
$-0.30
105.8% downside
Current Fair Value
105.8% downsideOvervalued by 105.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.53 Million |
|---|---|
| Enterprise Value | $-2,623,109.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-49.23 |
| Beta | -0.08 |
| Outstanding Shares | 301,333 |
Return
| Return on Equity | -253.57% |
|---|---|
| Return on Assets | -196.18% |
| Return on Invested Capital | -240.87% |
Valuation & Multiples
| P/E Ratio | -0.05 |
|---|---|
| PEG | 0.22 |
| Price to Sales | - |
| Price to Book Ratio | 0.32 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.22 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-6.48
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-7.02
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.32%▼ 1.85% |
|---|---|
| Total Invested | $131,972▼ 61.82% |
| Investors Holding | 100% |
ESG Score
No data
About Artelo Biosciences Inc
3 employeesArtelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting lipid signaling pathways including the endocannabinoid system. Artelo is rap...